RIAltO logo

RIAltO

A Randomised Investigation of Alternative Ofatumumab-containing regimens in less fit patients with CLL

RIAltO

A Randomised Investigation of Alternative Ofatumumab-containing regimens in less fit patients with CLL
Funding Novartis, Chugai Pharma Co.& Gilead, Napp
Portfolio Cancer
Interventions Medicine
Randomised Yes
Status In Follow-up
Start Date 07-Dec-2011

This trial is looking at using ofatumumab with bendamustine or chlorambucil chemotherapy for people with chronic lymphocytic leukaemia who cannot have intensive treatment.

Publications

  • Abstract/poster: Brief exposure to idelalisib may improve the long-term efficacy of frontline chemoimmunotherapy in chronic lymphocytic leukaemia: 3-year follow-up from the RIAltO trial